Updates from SABCS 2022 - Metastatic Breast Cancer Trial Talk

Conference Talk

The San Antonio Breast Cancer Symposium was held December 6-10, 2022 virtually and in San Antonio, Texas. Read below for MBC research updates from this meeting.

In addition, the Black Wo(Men) Speak Symposium was held in conjunction with SABCS 2022. This symposium, which was a follow-up to the Metastatic Breast Cancer Alliance’s BECOME project and similar efforts from other groups, discussed the urgent need for greater diversity in clinical trials by presenting results from recent surveys. The goal of this collaborative effort is to break down barriers to clinical trial participation, increase trust in the healthcare system, and ensure access to clinical trials. A summary and other information covered in this symposium is expected in early 2023. Watch for links to this information in a future issue of Metastatic Trial Talk.

MBC Research Updates from SABCS 2022
Overview of Emerging Treatments for MBC
Trastuzumab Deruxtecan (Enhertu®) for HER2-Low and HER2-Positive MBC
 Sacituzumab Govitecan (Trodelvy®) in HR+, HER2- MBC
 Antibody-Drug Conjugates
 Tumor Cells Found in Blood for Treatment Selection



for past articles or specific information.